A long‐term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double‐blind, parallel‐group comparison trial

医学 格列齐特 内科学 2型糖尿病 糖尿病 随机对照试验 期限(时间) 安慰剂 2型糖尿病 吡格列酮 双盲 内分泌学 替代医学 量子力学 病理 物理
作者
B. Charbonnel,David R. Matthews,Guntram Schernthaner,Markolf Hanefeld,P Brunetti
出处
期刊:Diabetic Medicine [Wiley]
卷期号:22 (4): 399-405 被引量:131
标识
DOI:10.1111/j.1464-5491.2004.01426.x
摘要

Abstract Aims This study compared the effects of pioglitazone and gliclazide on metabolic control in drug‐naïve patients with Type 2 diabetes mellitus. Methods A total of 1270 patients with Type 2 diabetes were randomized in a parallel‐group, double‐dummy, double‐blind study. Patients with poorly controlled Type 2 diabetes (HbA 1c 7.5–11%), despite dietary advice, received either pioglitazone up to 45 mg once daily or gliclazide up to 160 mg two times daily. Primary efficacy endpoint was change in HbA 1c from baseline to the end of the study. Secondary efficacy endpoints included change in fasting plasma glucose, fasting plasma insulin and plasma lipids. At selected centres, oral glucose tolerance tests were performed and C‐peptide and pro‐insulin levels were measured. Results Mean HbA 1c values decreased by the same amount in the two treatment groups from baseline to week 52 [pioglitazone: −1.4%; gliclazide: −1.4%; (90% CI: −0.18 to 0.02)]. A significantly greater mean reduction in fasting plasma glucose was observed in the pioglitazone group (2.4 mmol/l) than in the gliclazide group [2.0 mmol/l; treatment difference −0.4 mmol/l in favour of pioglitazone; P = 0.002; (95% CI: −0.7 to −0.1)]. Improvements in high‐density lipoprotein cholesterol (HDL‐C) and total cholesterol/HDL‐C were greater with pioglitazone than with gliclazide ( P < 0.001). The frequencies of adverse events were comparable between the two treatment groups, but more hypoglycaemic events were reported for gliclazide, whereas twice as many patients reported oedema with pioglitazone than with gliclazide. Conclusions Pioglitazone monotherapy was equivalent to gliclazide in reducing HbA 1c , with specific differences between treatments in terms of mechanism of action, plasma lipids and adverse events.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
搞怪的松鼠完成签到,获得积分10
刚刚
1秒前
hh完成签到,获得积分10
1秒前
JF123_发布了新的文献求助10
2秒前
2秒前
yy030421完成签到,获得积分10
2秒前
炙热的翠曼完成签到,获得积分10
3秒前
4秒前
请赐我文献完成签到,获得积分10
4秒前
4秒前
上官若男的应助被霖29采纳,获得10
5秒前
donkey完成签到,获得积分10
5秒前
嫑嫑发布了新的文献求助10
6秒前
行走发布了新的文献求助20
6秒前
高贵魂幽完成签到,获得积分10
6秒前
6秒前
藏识完成签到,获得积分10
7秒前
lei发布了新的文献求助10
7秒前
8秒前
romarola发布了新的文献求助10
8秒前
羽6发布了新的文献求助10
9秒前
9秒前
10秒前
8Km完成签到,获得积分10
10秒前
zhouyuhan完成签到,获得积分10
10秒前
GY00完成签到,获得积分10
11秒前
胡雅琴完成签到,获得积分10
11秒前
马家辉完成签到,获得积分10
12秒前
稳重笑阳完成签到 ,获得积分10
13秒前
せん发布了新的文献求助10
14秒前
14秒前
风清扬的应助被鲁滨孙采纳,获得10
14秒前
14秒前
周周发布了新的文献求助30
15秒前
李洁完成签到,获得积分10
15秒前
小马甲的应助被cyl采纳,获得10
15秒前
wangwang完成签到,获得积分10
15秒前
两块钱完成签到,获得积分10
16秒前
17秒前
心灵美砖头完成签到,获得积分0
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185762
求助须知:如何正确求助?哪些是违规求助? 9574458
关于积分的说明 21836217
捐赠科研通 7783574
什么是DOI,文献DOI怎么找? 3434651
关于科研通互助平台的介绍 2559017
邀请新用户注册赠送积分活动 2481466